Literature DB >> 6212231

Pharmacokinetic and clinical evaluation of moxalactam in infants and children.

R Latif, M C Thirumoorthi, J A Buckley, D M Kobos, M K Aravind, R E Kauffman, A S Dajani.   

Abstract

37 patients ranging in age from 9 months to 14 years, with various infections, were treated with moxalactam. The pharmacokinetics of the drug were studied in 18 patients. The mean plasma concentration 1 h after a 25 mg/kg intravenous dose was 41.4 micrograms/ml +/- 15.6 SD, the half-life was 1.5 h +/- 0.4 SD and the mean Vd was 550 ml/kg +/- 239 SD. The total body clearance of moxalactam was 4.1 ml/min/kg +/- 1.5 SD and the mean renal clearance 4.5 ml/min/kg +/- 2.8 SD. Between 52 and 107% of the administered dose was recovered in the urine within 8 h after administration. The pharmacokinetics after the first and multiple doses of moxalactam were similar, indicating no accumulation of the drug with repeated administration. The clinical response was adequate in 35 of 37 patients. Moxalactam was well tolerated and only minor and transient hematological abnormalities were observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6212231     DOI: 10.1159/000457446

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  3 in total

1.  Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Authors:  Yang Wang; Dan Sun; Yan Mei; Sanlan Wu; Xinlin Li; Sichan Li; Jun Wang; Liuliu Gao; Hua Xu; Yali Tuo
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.